Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.
NCT ID: NCT04061395
Last Updated: 2024-04-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
20 participants
INTERVENTIONAL
2019-10-01
2022-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The total duration of the treatment period per subject is 16 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT03628924
Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.
NCT04084665
A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa
NCT01704534
Anakinra as a Treatment for Hydradenitis Suppurativa
NCT01516749
Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03001622
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Guselkumab
Guselkumab 200 mg Q4W; subcutaneous injections; duration of 16 weeks.
Guselkumab
See study arm description.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Guselkumab
See study arm description.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* treatment history of at least one systemic anti-inflammatory / immunosuppressive agent;
* HS diagnosis of at least 1 year;
* minimum of two anatomical locations with HS lesions
* minimum of 4 active abscesses and/or inflammatory nodules (AN).
Exclusion Criteria
* previous use of guselkumab;
* use of treatment with biologics or any immunosuppressives for HS in the last 3 months prior to randomization;
* presence of other uncontrolled major disease;
* pregnant or lactating women
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen-Cilag Ltd.
INDUSTRY
University Medical Center Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erasmus MC, University Medical Center Rotterdam
Rotterdam, South Holland, Netherlands
University Medical Center Groningen
Groningen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNTO1959HDS2002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.